51
|
Grassia G, Maddaluno M, Guglielmotti A, Mangano G, Biondi G, Maffia P, Ialenti A. The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res 2009; 84:485-93. [PMID: 19592568 PMCID: PMC2777949 DOI: 10.1093/cvr/cvp238] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2008] [Revised: 06/30/2009] [Accepted: 07/08/2009] [Indexed: 12/12/2022] Open
Abstract
AIMS Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wire-induced carotid injury in apolipoprotein E-deficient (apoE(-/-)) mice. METHODS AND RESULTS Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 microM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE(-/-) mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE(-/-) mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. CONCLUSION This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.
Collapse
MESH Headings
- Animals
- Anti-Inflammatory Agents/pharmacology
- Apolipoproteins E/genetics
- Apolipoproteins E/metabolism
- Carotid Arteries/drug effects
- Carotid Arteries/metabolism
- Carotid Artery Injuries/metabolism
- Carotid Artery Injuries/pathology
- Cell Movement/drug effects
- Cell Proliferation/drug effects
- Cells, Cultured
- Chemokine CCL2/antagonists & inhibitors
- Chemokine CCL2/metabolism
- Disease Models, Animal
- Female
- Hyperlipidemias/metabolism
- Hyperlipidemias/pathology
- Indazoles/pharmacology
- Male
- Mice
- Mice, Knockout
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Propionates/pharmacology
- Rats
- Rats, Wistar
Collapse
Affiliation(s)
- Gianluca Grassia
- Department of Experimental Pharmacology, University of Naples Federico II, Via Domenico Montesano, 49, 80131 Naples, Italy
| | - Marcella Maddaluno
- Department of Experimental Pharmacology, University of Naples Federico II, Via Domenico Montesano, 49, 80131 Naples, Italy
| | - Angelo Guglielmotti
- Angelini R&D, Angelini Research Center, 00040 S.Palomba-Pomezia, Rome, Italy
| | - Giorgina Mangano
- Angelini R&D, Angelini Research Center, 00040 S.Palomba-Pomezia, Rome, Italy
| | - Giuseppe Biondi
- Angelini R&D, Angelini Research Center, 00040 S.Palomba-Pomezia, Rome, Italy
| | - Pasquale Maffia
- Department of Experimental Pharmacology, University of Naples Federico II, Via Domenico Montesano, 49, 80131 Naples, Italy
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, UK
- School of Biotechnological Sciences, University of Naples Federico II, Naples, Italy
| | - Armando Ialenti
- Department of Experimental Pharmacology, University of Naples Federico II, Via Domenico Montesano, 49, 80131 Naples, Italy
| |
Collapse
|
52
|
Takemoto Y, Kawata H, Soeda T, Imagawa K, Somekawa S, Takeda Y, Uemura S, Matsumoto M, Fujimura Y, Jo JI, Kimura Y, Tabata Y, Saito Y. Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis. Arterioscler Thromb Vasc Biol 2009; 29:857-62. [DOI: 10.1161/atvbaha.109.186429] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Yasuhiro Takemoto
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Hiroyuki Kawata
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Tsunenari Soeda
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Keiichi Imagawa
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Satoshi Somekawa
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Yukiji Takeda
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Shiro Uemura
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Masanori Matsumoto
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Yoshihiro Fujimura
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Jun-ichiro Jo
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Yu Kimura
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Yasuhiko Tabata
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| | - Yoshihiko Saito
- From the First Department of Internal Medicine (Y.T., H.K., T.S., K.I., S.S., Y.T., S.U., Y.S. and Blood Transfusion Medicine (M.M., Y.F.), Nara Medical University, Japan; and the Department of Biomaterials (U.J., Y.K., Y.T.), Field of Tissue Engineering, Kyoto University, Kyoto, Japan
| |
Collapse
|